Therefore the overall impact of 2.17-mAlb on tumor growth was determined not only by the direct effects of LepR antagonist on tumor cells and/or other cells supporting tumor growth, but also by other systemic factors such as insulin metabolism that are regulated by leptin. The gene discussed is LEPR; the disease is neoplasm.